medicine-news-1/inoperable-colon-cancer-resolved-after-four-months-of-new-treatment--59114-2/;/a><br

Breaking Biology Technology:ATS Medical Announces CE Mark Approval for the ATS 3f Enable Bioprosthesis 2 ATS Medical Announces CE Mark Approval for the ATS 3f Enable Bioprosthesis 3 ATS Medical Announces CE Mark Approval for the ATS 3f Enable Bioprosthesis 4 Merrimack Pharmaceuticals Acquires Hermes Biosciences, Inc. 2 Merrimack Pharmaceuticals Acquires Hermes Biosciences, Inc. 3 NIST researchers put a new spin on atomic musical chairs 2 JourneyLite of Houston Now Offering Sleeve Gastrectomy 2

[0] ATS Medical Announces CE Mark Approval for the ATS 3f Enable Bioprosthesis [0] Merrimack Pharmaceuticals Acquires Hermes Biosciences, Inc. [0] NIST researchers put a new spin on atomic musical chairs [0] JourneyLite of Houston Now Offering Sleeve Gastrectomy

Breaking Medicine Technology:Q-Med AB and Oceana Therapeutics, Inc. Take Major Step Towards SOLESTA(TM) US Regulatory Filing 2 Q-Med AB and Oceana Therapeutics, Inc. Take Major Step Towards SOLESTA(TM) US Regulatory Filing 3 Keryx Biopharmaceuticals, Inc. Reports Updated Phase 1/2 Data, Including New Survival Data, on KRX-0401 (Perifosine) in the Treatment of Advanced Multiple Myeloma at the 51st Annual Meeting of the American Society of Hematology 2 Keryx Biopharmaceuticals, Inc. Reports Updated Phase 1/2 Data, Including New Survival Data, on KRX-0401 (Perifosine) in the Treatment of Advanced Multiple Myeloma at the 51st Annual Meeting of the American Society of Hematology 3 Keryx Biopharmaceuticals, Inc. Reports Updated Phase 1/2 Data, Including New Survival Data, on KRX-0401 (Perifosine) in the Treatment of Advanced Multiple Myeloma at the 51st Annual Meeting of the American Society of Hematology 4 Keryx Biopharmaceuticals, Inc. Reports Updated Phase 1/2 Data, Including New Survival Data, on KRX-0401 (Perifosine) in the Treatment of Advanced Multiple Myeloma at the 51st Annual Meeting of the American Society of Hematology 5 Keryx Biopharmaceuticals, Inc. Reports Updated Phase 1/2 Data, Including New Survival Data, on KRX-0401 (Perifosine) in the Treatment of Advanced Multiple Myeloma at the 51st Annual Meeting of the American Society of Hematology 6 Keryx Biopharmaceuticals, Inc. Reports Updated Phase 1/2 Data, Including New Survival Data, on KRX-0401 (Perifosine) in the Treatment of Advanced Multiple Myeloma at the 51st Annual Meeting of the American Society of Hematology 7 Amgen Board Authorizes $5 Billion Increase in Stock Repurchase Program 2 Amgen Board Authorizes $5 Billion Increase in Stock Repurchase Program 3 Sysmex Supports Illinois Chapter Leukemia and Lymphoma Society 52505 1 Sysmex Supports Illinois Chapter Leukemia and Lymphoma Society 52505 2 President Obamas Health Care Plan 3A Too Big Too Expensive Too Rushed 52500 1 President Obamas Health Care Plan 3A Too Big Too Expensive Too Rushed 52500 2 President Obamas Health Care Plan 3A Too Big Too Expensive Too Rushed 52500 3 St Johns Hospital Acquires Latest Technology in Robotic Assisted Surgery 13163 1 St Johns Hospital Acquires Latest Technology in Robotic Assisted Surgery 13163 2

[0] Q-Med AB and Oceana Therapeutics, Inc. Take Major Step Towards SOLESTA(TM) US Regulatory Filing [0] Keryx Biopharmaceuticals, Inc. Reports Updated Phase 1/2 Data, Including New Survival Data, on KRX-0401 (Perifosine) in the Treatment of Advanced Multiple Myeloma at the 51st Annual Meeting of the American Society of Hematology [0] Amgen Board Authorizes $5 Billion Increase in Stock Repurchase Program